Literature DB >> 22326439

Increased S100B+ NK cell counts in acutely ill schizophrenia patients are correlated with the free cortisol index, but not with S100B serum levels.

Johann Steiner1, Sabine Westphal, Matthias L Schroeter, Kolja Schiltz, Wolfgang Jordan, Ulf J Müller, Hans-Gert Bernstein, Bernhard Bogerts, Reinhold E Schmidt, Roland Jacobs.   

Abstract

Several studies have provided evidence for increased S100B serum concentrations in schizophrenia. The pathophysiological significance of this finding is still uncertain because S100B is involved in many cellular mechanisms and is not astrocyte-specific as was previously assumed. S100B is also expressed by subsets of CD3+ CD8+ T cells and natural killer (NK) cells and may therefore be linked to the immune hypothesis of schizophrenia. We have quantified S100B+ CD3+ CD8+ T cells and NK cells by flow cytometry in the peripheral blood of 26 acutely ill schizophrenia cases and 32 matched controls. In parallel, S100B concentrations and the free cortisol index (FCI), a surrogate marker for stress axis activity, were determined in serum samples from the same blood draw. Psychopathology was monitored using the Positive and Negative Syndrome Scale (PANSS). The patient group had increased S100B+ NK cell counts (P=0.045), which correlated with the FCI (r=0.299, P=0.026) but not with the PANSS or the elevated (P=0.021) S100B serum concentrations. S100B+ CD3+ CD8+ T cell counts were not significantly changed in the patient group and did neither correlate with the FCI and PANSS, nor with S100B serum concentrations. In conclusion, despite the observation of an increase in S100B+ NK cells in schizophrenia patients, the lack of a correlation with serum S100B concentrations suggests that these cells are probably not a major source of S100B in the blood of schizophrenia patients. Notably, elevated S100B+ NK cell counts may be linked with stress axis activation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22326439     DOI: 10.1016/j.bbi.2012.01.018

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  6 in total

1.  S100B is downregulated in the nuclear proteome of schizophrenia corpus callosum.

Authors:  Johann Steiner; Andrea Schmitt; Matthias L Schroeter; Bernhard Bogerts; Peter Falkai; Christoph W Turck; Daniel Martins-de-Souza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-02-07       Impact factor: 5.270

Review 2.  Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics.

Authors:  Chi-Yu Lai; Elizabeth Scarr; Madhara Udawela; Ian Everall; Wei J Chen; Brian Dean
Journal:  World J Psychiatry       Date:  2016-03-22

3.  CD166/ALCAM mediates proinflammatory effects of S100B in delayed type hypersensitivity.

Authors:  Rüdiger von Bauer; Dimitrios Oikonomou; Alba Sulaj; Sawsan Mohammed; Agnes Hotz-Wagenblatt; Hermann-Josef Gröne; Bernd Arnold; Christine Falk; Dorit Luethje; Axel Erhardt; David M Stern; Angelika Bierhaus; Peter P Nawroth
Journal:  J Immunol       Date:  2013-05-31       Impact factor: 5.422

4.  Levels of S100B are raised in female patients with schizophrenia.

Authors:  Kara O'Connell; Jogin Thakore; Kumlesh K Dev
Journal:  BMC Psychiatry       Date:  2013-05-24       Impact factor: 3.630

Review 5.  Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia.

Authors:  Katina Aleksovska; Emanuele Leoncini; Stefano Bonassi; Alfredo Cesario; Stefania Boccia; Alessandra Frustaci
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

6.  Peripheral Immune Cell Populations Associated with Cognitive Deficits and Negative Symptoms of Treatment-Resistant Schizophrenia.

Authors:  Emilio Fernandez-Egea; Petra E Vértes; Shaun M Flint; Lorinda Turner; Syed Mustafa; Alex Hatton; Kenneth G C Smith; Paul A Lyons; Edward T Bullmore
Journal:  PLoS One       Date:  2016-05-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.